Qingyun J. Liu

The paper develops RSPO2-based peptibody-drug conjugates that target LGR4/5/6 receptors, showing potent anti-tumor activity in colorectal cancer and neuroblastoma models.

This study develops and tests a camptothecin analog conjugate targeting LGR4/5/6 in CRC models, showing potent anti-tumor activity with minimal toxicity.

This study identifies an anti-GPR56 monoclonal antibody that enhances Src-Fak signaling and cell adhesion through a novel extracellular domain-dependent mechanism.